Denali racks up $130 mln Series B
South San Francisco-based Denali Therapeutics Inc, which is focused on developing treatments for patients with neurodegenerative diseases, has raised $130 million in Series B financing. Baillie Gifford led the round with participation from other investors that included ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures and the Alaska Permanent Fund.
26 August 2016•1 min read
